ES2743558T3 - Anticuerpos de-EphA3 - Google Patents

Anticuerpos de-EphA3 Download PDF

Info

Publication number
ES2743558T3
ES2743558T3 ES10777137T ES10777137T ES2743558T3 ES 2743558 T3 ES2743558 T3 ES 2743558T3 ES 10777137 T ES10777137 T ES 10777137T ES 10777137 T ES10777137 T ES 10777137T ES 2743558 T3 ES2743558 T3 ES 2743558T3
Authority
ES
Spain
Prior art keywords
antibody
sequence
amino acid
seq
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10777137T
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Luehrsen
David Martinez
Christina Yi
Christopher R Bebbington
Geoffrey T Yarranton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanigen Inc
Original Assignee
Humanigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanigen Inc filed Critical Humanigen Inc
Application granted granted Critical
Publication of ES2743558T3 publication Critical patent/ES2743558T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES10777137T 2009-10-14 2010-10-14 Anticuerpos de-EphA3 Active ES2743558T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25166809P 2009-10-14 2009-10-14
PCT/US2010/052725 WO2011053465A1 (en) 2009-10-14 2010-10-14 Antibodies to epha3

Publications (1)

Publication Number Publication Date
ES2743558T3 true ES2743558T3 (es) 2020-02-19

Family

ID=43499991

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10777137T Active ES2743558T3 (es) 2009-10-14 2010-10-14 Anticuerpos de-EphA3

Country Status (11)

Country Link
US (2) US8664365B2 (https=)
EP (1) EP2488554B1 (https=)
JP (2) JP2013508292A (https=)
CN (1) CN102666589B (https=)
AU (1) AU2010313621C1 (https=)
CA (1) CA2777068C (https=)
DK (1) DK2488554T3 (https=)
ES (1) ES2743558T3 (https=)
PL (1) PL2488554T3 (https=)
PT (1) PT2488554T (https=)
WO (1) WO2011053465A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011235867B2 (en) * 2010-04-01 2015-12-03 Kalobios Pharmaceuticals, Inc. EphA3 antibodies for the treatment of multiple myeloma
WO2011160132A2 (en) * 2010-06-18 2011-12-22 Kalobios Pharmaceuticals, Inc. Detection of epha3 as a marker of the presence of a solid tumor
JP2014527054A (ja) 2011-08-12 2014-10-09 カロバイオス ファーマシューティカルズ インコーポレイティッド 骨髄内の異常血管系上に発現したＥｐｈＡ３を標的とすることによる、血液増殖性疾患を処置する方法
PH12021552742A1 (en) 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
US20170145103A1 (en) 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
WO2018053032A1 (en) * 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
EP3758751A4 (en) 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
IL291937A (en) * 2019-10-09 2022-06-01 Council Queensland Inst Medical Res Direct link to epha3 and its uses
TW202134278A (zh) * 2019-11-08 2021-09-16 美商胡曼尼根公司 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞
EP4232470A4 (en) * 2020-10-23 2025-01-15 Atreca, Inc. ANTIBODIES AGAINST CORONAVIRUS SARS-COV-2
CN118055945A (zh) * 2021-08-06 2024-05-17 韩国生命工学研究院 新型抗epha2嵌合抗原受体和表达其的免疫细胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0590030B1 (en) 1991-06-21 2004-09-29 The Walter and Eliza Hall Institute of Medical Research A receptor-type tyrosine kinase [human eph/elk-like kinase - hek] and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
US20060134098A1 (en) 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en) 2006-11-17 2008-05-22 Sang Yun Park Rotative force generator
AU2008226905C1 (en) 2007-03-08 2014-11-06 Humanigen, Inc. EphA3 antibodies for the treatment of solid tumors
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
AU2010221159B2 (en) 2009-03-06 2015-11-26 Humanigen, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

Also Published As

Publication number Publication date
US9290571B2 (en) 2016-03-22
JP2016094424A (ja) 2016-05-26
JP2013508292A (ja) 2013-03-07
US8664365B2 (en) 2014-03-04
WO2011053465A1 (en) 2011-05-05
CA2777068C (en) 2020-05-26
PL2488554T3 (pl) 2020-03-31
EP2488554A1 (en) 2012-08-22
AU2010313621C1 (en) 2015-11-26
DK2488554T3 (da) 2019-09-02
CA2777068A1 (en) 2011-05-05
PT2488554T (pt) 2019-09-13
US20140120114A1 (en) 2014-05-01
EP2488554B1 (en) 2019-07-24
CN102666589A (zh) 2012-09-12
AU2010313621B2 (en) 2015-07-30
CN102666589B (zh) 2014-08-20
US20110123549A1 (en) 2011-05-26
AU2010313621A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
ES2743558T3 (es) Anticuerpos de-EphA3
CN111683970B (zh) C-kit结合剂
ES2860988T3 (es) Anticuerpos anti-TFR y su uso en el tratamiento de trastornos proliferativos e inflamatorios
ES2942636T3 (es) Proteínas de unión a IL-11R y usos de las mismas
EP2280732B1 (en) Antibodies to granulocyte-macrophage colony-stimulating factor
KR20220050971A (ko) 신규 항-cd39 항체
CN112062853A (zh) 双特异性her2抗体及使用方法
MX2012012790A (es) Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
WO2021222861A1 (en) Antibodies specific to abcb5 and uses thereof
CN115151307A (zh) 抗mertk抗体和其使用方法
CA3183389A1 (en) Bispecific antibody and use thereof
CN118076638A (zh) 新型抗sirpa抗体
US20190352386A1 (en) Highly potent monoclonal antibodies to angiogenic factors
US11820816B2 (en) Anti-VEGF antibodies and methods of use
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
CN103747801A (zh) 抗emr1抗体
WO2022052846A1 (zh) 抗cd47抗体及其用途
CN117157314A (zh) Pd-l1抗体、融合蛋白及其用途
HK40106257A (zh) 新型抗sirpa抗体
HK40109194A (zh) 抗体
HK40110414A (zh) 抗her2抗体及其使用方法
HK40075433A (en) Anti-mertk antibodies and methods of use thereof
HK1235412A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
HK40040431B (zh) 双特异性her2抗体及使用方法
HK1148222A (en) Antibodies to granulocyte-macrophage colony-stimulating factor